X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (31) 31
index medicus (19) 19
humans (18) 18
female (13) 13
cancer (10) 10
breast cancer (8) 8
breast neoplasms - drug therapy (8) 8
trastuzumab (7) 7
antineoplastic agents - therapeutic use (6) 6
breast neoplasms - pathology (6) 6
clinical trials as topic (6) 6
treatment outcome (6) 6
animals (5) 5
breast neoplasms - genetics (5) 5
care and treatment (5) 5
neoplasms - drug therapy (5) 5
risk factors (5) 5
adult (4) 4
article (4) 4
clinical trials (4) 4
drug approval (4) 4
drug development (4) 4
phase-ii (4) 4
survival (4) 4
united states (4) 4
aged (3) 3
cardiotoxicity (3) 3
cell lung-cancer (3) 3
chemotherapy (3) 3
disease-free survival (3) 3
male (3) 3
management (3) 3
middle aged (3) 3
myocarditis (3) 3
oncology, experimental (3) 3
protein kinase inhibitors - therapeutic use (3) 3
randomized controlled trials as topic (3) 3
research (3) 3
research design (3) 3
therapy (3) 3
united states food and drug administration (3) 3
aged, 80 and over (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
atp-binding cassette, sub-family b, member 1 - antagonists & inhibitors (2) 2
atp-binding cassette, sub-family b, member 1 - metabolism (2) 2
biomarkers, tumor (2) 2
blood-brain-barrier (2) 2
breast (2) 2
breast neoplasms - metabolism (2) 2
breast neoplasms - mortality (2) 2
breast-cancer (2) 2
carcinoma (2) 2
cardiac & cardiovascular systems (2) 2
cardio-oncology (2) 2
cardiology (2) 2
cardiovascular diseases (2) 2
complications (2) 2
docetaxel (2) 2
drug resistance (2) 2
drug therapy (2) 2
immunohistochemistry (2) 2
lapatinib plus capecitabine (2) 2
medical services (2) 2
medicine & public health (2) 2
multidrug-resistance (2) 2
neoplasm metastasis (2) 2
nervous-system metastases (2) 2
nonclinical model (2) 2
open-label (2) 2
p-glycoprotein (2) 2
patient selection (2) 2
patients (2) 2
pharmacology & pharmacy (2) 2
phase-ii trial (2) 2
piperazines - therapeutic use (2) 2
pre-clinical model (2) 2
pyridines - therapeutic use (2) 2
receptor (2) 2
receptor, erbb-2 - genetics (2) 2
receptor, erbb-2 - metabolism (2) 2
receptors, estrogen - metabolism (2) 2
renal-cell carcinoma (2) 2
solid tumors (2) 2
subtypes (2) 2
toxicity (2) 2
trial (2) 2
trials (2) 2
tumor-infiltrating lymphocytes (2) 2
tyrosine kinase inhibitor (2) 2
usage (2) 2
18f fluoropaclitaxel (1) 1
1st-line treatment (1) 1
99mtc-sestamibi (1) 1
abc transporter (1) 1
abc transporters (1) 1
acute myeloid-leukemia (1) 1
acute-myeloid-leukemia (1) 1
adjudication (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 04/2012, Volume 104, Issue 8, pp. 568 - 569
Achieving success in the development of a cancer drug continues to be challenging. Here, Amiri-Kordestani and Fojo discuss the high percentage of negative... 
SURVIVAL | BENEFIT | ONCOLOGY | END-POINT | DRUG DEVELOPMENT | TARGETED AGENTS | CANCER | CHEMOTHERAPY | STABLE DISEASE | DESIGNS | Treatment Outcome | Clinical Trials, Phase III as Topic | Antineoplastic Agents - therapeutic use | Humans | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Clinical trials | Oncology | Cancer | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1011 - 1012
Resources are needed to assist patients in understanding their diagnoses and considering treatment options. This commentary focuses on improving the language... 
ONCOLOGY | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 06/2012, Volume 104, Issue 11, p. 885
Journal Article
The Oncologist, ISSN 1083-7159, 08/2018, Volume 23, Issue 8, pp. 874 - 878
Immune checkpoint inhibitors are a class of drugs that trigger the immune system to recognize and fight cancer cells; however, related immune‐related adverse... 
Myocarditis | Immune checkpoint inhibitor | Project Data Sphere | PD‐1/PD‐L1 inhibitor | Immune‐related adverse events | Immune-related adverse events | PD-1/PD-L1 inhibitor | MANAGEMENT | FATAL MYOCARDITIS | THERAPY | PEMBROLIZUMAB | ONCOLOGY | PD-L1 inhibitor | PATIENT | NIVOLUMAB | PD-1 | IPILIMUMAB | FULMINANT MYOCARDITIS | PD‐L1 inhibitor | Commentaries | PD‐1
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 09/2013, Volume 105, Issue 18, pp. 1340 - 1342
  Two of the most perplexing problems in breast cancer, inflammatory breast cancer (IBC) and obesity, are linked in the report by Schairer and colleagues in... 
DENSITY | ONCOLOGY | SUBTYPES | EXPRESSION | CARCINOMA | Body Mass Index | Parturition | Inflammatory Breast Neoplasms - epidemiology | Humans | Female | Educational Status | Receptors, Estrogen - analysis | Obesity | Oncology | Breast cancer | Risk factors | Public health | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2012, Volume 18, Issue 1, pp. 23 - 32
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2012, Volume 104, Issue 9, p. 718
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2018, Volume 36, Issue 15, pp. 3009 - 3009
Conference Proceeding
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2016, Volume 155, Issue 2, pp. 235 - 251
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2014, Volume 20, Issue 17, pp. 4436 - 4441
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1225 - 1231
PurposeThe outcome and proportion of patients with bone-only (BO) metastatic breast cancer (MBC) has not been well described. We sought to describe the... 
RISK | COMPLICATIONS | MANAGEMENT | ONCOLOGY | DISEASE | ORIGINAL REPORTS
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 10, pp. 2949 - 2955
On December 20, 2017, the FDA granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients... 
TRASTUZUMAB | ONCOLOGY | PACLITAXEL
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 4968 - 4972
On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.